Join

Compare · NVO vs WVE

NVO vs WVE

Side-by-side comparison of Novo Nordisk A/S (NVO) and Wave Life Sciences Ltd. (WVE): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both NVO and WVE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVO is the larger of the two at $183.15B, about 167.0x WVE ($1.10B).
  • Over the past year, NVO is down 45.3% and WVE is down 18.9% - WVE leads by 26.4 points.
  • NVO has been more active in the news (8 items in the past 4 weeks vs 5 for WVE).
  • NVO has more recent analyst coverage (25 ratings vs 20 for WVE).
PerformanceNVO-45.28%WVE-18.92%
2025-06-09+0.00%2026-06-09
MetricNVOWVE
Company
Novo Nordisk A/S
Wave Life Sciences Ltd.
Price
$41.23+0.55%
$5.72+0.53%
Market cap
$183.15B
$1.10B
1M return
-10.39%
-20.06%
1Y return
-45.28%
-18.92%
Sector
Health Care
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
NASDAQ
IPO
2015
News (4w)
8
5
Recent ratings
25
20
NVO

Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

WVE

Wave Life Sciences Ltd.

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It develops WVE-120101 and WVE-120102, a stereopure therapeutic candidates, which are in Phase 1b/2a clinical trials for the treatment of Huntington's disease (HD); WVE-003, mutant huntingtin SNP3 program for the treatment of HD; WVE-004, C9orf72 program for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-N531, our Exon 53 program for the treatment of Duchenne muscular dystrophy; and ATXN3 program in SCA3. The company has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, and University of Massachusetts. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

Latest NVO

Latest WVE